PARLIAMENTARY WRITTEN QUESTION
Avelumab (1 November 2021)
Question Asked
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the reasons for NICE's refusal to make Avelumb available on the NHS in England.
Asked by:
Fleur Anderson (Labour)
Asked by:
Fleur Anderson (Labour)
Answer
We have made no such assessment. The National Institute for Health and Care Excellence (NICE) is an independent body responsible for developing recommendations in line with its published methods and processes.
NICE has published guidance recommending avelumab for use in a number of cancers and it is now available to patients.
NICE is currently developing guidance on the use of avelumab for use in the treatment of urothelial cancer.
Answered by:
Edward Argar (Conservative)
4 November 2021
Contains Parliamentary information licensed under the Open Parliament Licence v3.0.